Dr. Thomas Michael Papa, MD Internal Medicine - Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 175 E Brown St, Suite 114, East Stroudsburg, PA 18301 Phone: 570-426-2301 Fax: 570-426-2306 |
Susheer Gandotra, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 175 E Brown St, Suite 114, East Stroudsburg, PA 18301 Phone: 570-426-2301 Fax: 570-426-2306 |
Ginamarie Foglia, DO Internal Medicine - Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 500 Plaza Ct, Suite D, East Stroudsburg, PA 18301 Phone: 570-476-3778 Fax: 570-421-3493 |
Dr. Anubhav Kanwar, MBBS Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 175 E Brown St Dept Of, East Stroudsburg, PA 18301 Phone: 570-426-2840 Fax: 570-426-2796 |
News Archive
The C.A.R.E.S. Alliance, a new patient safety organization, today launched a range of online tools designed to help solve the growing problem of misuse and abuse of opioids by identifying the risks associated with these powerful pain medications. The free resources offered through the C.A.R.E.S. (Collaborating & Acting Responsibly to Ensure Safety) Alliance promote safety in prescribing, dispensing, using, storing and disposing of these commonly abused pain medications.
These Republican officials argue that as federal funding for Medicaid has expanded, so has federal control. Their argument to include the measure in debt-ceiling legislation is raising concern among some Medicaid advocates.
A technology to diagnose a potentially fatal disease in premature infants invented by Sunyoung Kim, PhD, Professor of Biochemistry & Molecular Biology at LSU Health New Orleans School of Medicine, has been granted a Breakthrough Device Designation by the Food and Drug Administration.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.
Questcor Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has informed Questcor that the FDA will require additional time beyond the current action date of September 11, 2010 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms.
› Verified 4 days ago